Your AI-Trained Oncology Knowledge Connection!
Dr Rafael Fonseca, MD, provides insight on the evidence around quadruplet versus triplet therapies in patients with newly diagnosed, transplant-eligible multiple myeloma, and how to select the appropriate treatment regimen for this patient population.
Depth of response and treatment duration in patients with newly diagnosed MM are discussed by Dr Fonseca.
Rafael Fonseca, MD reviews the MAIA clinical trial and strategies for choosing the appropriate patients with transplant-ineligible newly diagnosed MM.
Dr Fonseca discusses approaches for treating frail patients with multiple myeloma and those with high-risk disease.
Daratumumab effectiveness is evaluated as a frontline treatment approach versus in later lines of therapy in patients with multiple myeloma.
